cancers Article Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1) 1, , 2, 3 4 Ruth Ladenstein * y, Ulrike Pötschger y, Dominique Valteau-Couanet , Roberto Luksch , Victoria Castel 5 , Shifra Ash 6, Geneviève Laureys 7 , Penelope Brock 8, Jean Marie Michon 9, Cormac Owens 10, Toby Trahair 11, Godfrey Chi Fung Chan 12, Ellen Ruud 13, Henrik Schroeder 14, Maja Beck-Popovic 15, Guenter Schreier 16 , Hans Loibner 17, Peter Ambros 2, Keith Holmes 18, Maria Rita Castellani 4, Mark N. Gaze 19 , Alberto Garaventa 20, Andrew D.J. Pearson 21 and Holger N. Lode 22 1 St. Anna Children‘s Hospital and Children’s Cancer Research Institute (CCRI), Department of Paediatrics, Medical University, 1090 Vienna, Austria 2 Children’s Cancer Research Institute (CCRI), St. Anna Kinderkrebsforschung, Department of Paediatrics, Medical University, 1090 Vienna, Austria;
[email protected] (U.P.);
[email protected] (P.A.) 3 Children and Adolescent Oncology Department, Gustave Roussy, Paris-Sud, University, 94805 Villejuif, France;
[email protected] 4 Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy;
[email protected] (R.L.);
[email protected] (M.R.C.) 5 Hospital Universitario y Politecnico La Fe, 46026 Valencia, Spain;
[email protected] 6 Schneider Children‘s Medical Center of Israel, Sackler Faculty of Medicine Tel Aviv University, Petach, Tikvah 49202, Israel;
[email protected] 7 University Hospital Ghent,